Platelet-activating factor and arachidonic acid metabolites in psoriatic inflammation

British Journal of Dermatology

Volumn 134, Issue 6, 1996, Pages 1060-1064

  Izaki, S ^a   Yamamoto, T ^a   Goto, Y ^a   Ishimaru, S ^a   Yudate, F ^a   Kitamura, K ^a   Matsuzaki, M ^b  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

^b SRL INC   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; ETRETINATE; LEUKOTRIENE B4; LEUKOTRIENE C4; LEUKOTRIENE D4; LEUKOTRIENE E4; PROSTAGLANDIN E2; THROMBOCYTE ACTIVATING FACTOR; THROMBOXANE B2;

ADOLESCENT; ADULT; AGED; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PSORIASIS; PUSTULOSIS PALMOPLANTARIS; SCHOOL CHILD; SKIN INFLAMMATION;

EID: 0029956120     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2133.1996.tb07943.x     Document Type: Article

References (26)

1. Tagami H, Ofuji S. Characterization of a leukotactic factor derived from psoriatic scale. Br J Dermatol 1977; 97: 509-18.
2. Brain SD, Camp RDR, Dowd PM et al. Leukotriene B4-like material in scale of psoriatic skin lesions. Br J Pharmacol 1983; 83: 313-17.
3. Schroeder J-M. Chemotactic cytokines in the epidermis. Exp Dermatol 1992; 1: 12-19.
4. Sakamoto T, Elwood W, Barnes PJ, Chung KF. Effect of inhaled lysoplatelet-activating factor on airway microvascular leakage in the guinea pig. J Appl Physiol 1995; 74: 1117-22.
5. Chaussade S, Denizot Y, Colombel JF et al. Paf-acether in stool as marker of intestinal inflammation. Lancet 1992; 339: 739.
6. Zarco P, Maestre C, Herrero-Beaumont G et al. Involvement of platelet-activating factor and tumour necrosis factor in the pathogenesis of joint inflammation in rabbits. Clin Exp Immunol 1992; 88: 318-33.
7. Karashima T, Okubo K, Hachisuka H, Sasai Y, Bullous pemphigoid antigen expression in Pam 212 cells induced by the addition of platelet activating factor. Dermatologica 1991; 183: 265-8.
8. Mallet AI, Cunningham FM. Structural identification of platelet activating factor in psoriatic scale. Biochem Biophys Res Commun 1985; 126: 192-8.
9. Judge MR, Barr RM, Mallet AI et al. Platelet activating factor (PAF) and lyso-PAF in psoriasis. Arch Dermatol Res 1994; 286: 376-9.
10. Marks R, Barton SP, Shuttleworth D, Finlay AY. Assessment of disease progress in psoriasis. Arch Dermatol 1989; 125: 235-40.
11. Stafforini DM, Prescott SM, McIntyle TM. Human plasma platelet-activating acetylhydrolase. Purification and properties. J Biol Chem 1987; 262: 4223-30.
12. Matsuzaki M, Ishiguro Y, Tetsumoto T et al. PAF acetylhydrolase activities in human systemic lupus erythematosus and lupus-prone mice. Clin Chim Acta 1992; 210: 139-44.
13. Kawano K, Sugita S, Oka M, Tabata N. A simple, rapid and simultaneous extraction of thromboxane B2, 6-keto-prostaglandin F1alpha and prostaglandin E2. Jpn J Inflam 1987; 7: 511-15.
14. Mallet AI, Cunningham FM, Daniel R. Rapid isocratic high-performance liquid Chromatographic purification of platelet activating factor (PAF) and lyso-PAF from human skin. J Chromatogr 1984; 309: 160-4.
15. Archer CB, Page CP, Morley J, MacDonald DM. Accumulation of inflammatory cells in response to intracutaneous platelet activating factor (Paf-acether) in man. Br J Dermatol 1985; 112: 285-90.
16. Diez FL, Nieto ML, Fernandez-Gellardo S et al. Occupancy of platelet receptors for platelet-activating factor in patients with septicemia. J Clin Invest 1989; 83: 1733-40.
17. Sakaguchi K, Masugi F, Chen Y-H et al. Direct evidence of elevated levels of circulating platelet-activating factor in a patient with disseminated intravascular coagulation syndrome. J Lipid Mediators 1989; 1: 171-3.
18. Grandel KE, Farr RS, Wanderer AA et al. Association of platelet-activating factor with primary acquired cold urticaria. N Engl J Med 1985; 313: 405-9.
19. Camussi G, Aglietta M, Coda R et al. Release of platelet activating factor (PAF) and histamine. II. The cellular origin of human PAF: monocytes, polymorphonuclear neutrophils and basophils. Immunology 1981; 42: 191-9.
20. Lee T-C, Lenihan DJ, Malone B et al. Increased biosynthesis of platelet activating factor in activated human eosinophils. J Biol Chem 1984; 259: 5526-30.
21. Chignard M, LeCouedic JP, Tence M et al. The role of platelet-activating factor in platelet aggregation. Nature 1979; 279: 799-800.
22. Presortt SM, Zimmerman GA, McIntyre TM. Human endothelial cells in culture produce platelet-activating factor (1 -alkyl-2-acetyl-sn-glycero-i-phosphocholine) when stimulated with thrombin. Pror Natl Acad Sci USA 1984; 81: 3534-8.
23. Damtew B, Spagnuolo PJ. Platelet activating factor amplifies human neutrophil adherence to bovine endothelial cells - evidence for a lipoxygenase dependent mechanism. Inflammation 1992; 16: 425-36.
24. Bautista AP, Spitzer JJ. Platelet activating factor stimulates and primes the liver, Kupffer cells and neutrophils to release superoxide anion. Free Radical Res Commun 1992; 17: 195-209.
25. Heller R, Bussolino F, Ghigo D et al. Human endothelial cells are target for platelet-activating factor. 2. Platelet-activating factor induces platelet-activating factor synthesis in human umbilical vein endothelial cells. J Immunol 1992; 149: 3682-8.
26. Thivierge M, Rolapleszczynski M. Platelet-activating factor enhances interleukin-6 production by alveolar macrophages. J Allergy Clin Immunol 1992; 90: 796-802.